---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-011897"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:39:17.183620+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals prices upsized $275M 2.25% convertible notes due 2029

## Summary
- Aggregate principal $275M (upsized from $250M); net proceeds ~$266.8M (or ~$306.8M if full option exercised).
- Notes bear 2.25% interest semi-annually, mature Sept 1, 2029; initial conversion price ~$74.11/share, 30% premium.
- Proceeds: ~$35.3M for capped call transactions; remainder to repay existing senior secured term loan facility.
- Company plans new $325M delayed draw term loan and $75M revolving facility concurrently with closing.
- Initial purchasers have 13-day option to purchase additional $41.25M principal amount of notes.

## SEC filing metadata
- accession: 0000950103-24-011897
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000095010324011897/0000950103-24-011897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000095010324011897/dp216242_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-011897
- JSON: https://secwatch.observer/filing/0000950103-24-011897.json
- Plain text: https://secwatch.observer/filing/0000950103-24-011897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.